The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact over standard of care.

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations.

Data indicates that the therapy resulted in visual acuity gains and “achieved” non-inferiority to aflibercept at most time points through a 36-week period. The trial included 52 participants who were ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Celltrion’s aflibercept biosimilar, CT-P42, has not yet been approved by the FDA. Stay tuned to Big Molecule Watch as we continue to monitor key developments in ongoing BPCIA litigations and the ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in combination with 2 mg aflibercept did not meet its primary endpoint, according to ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient populationUBX1325 was ...

UNITY Biotechnology (UBX) announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...